Cargando…
High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions
The urokinase-type plasminogen activator receptor (uPAR) is an essential regulator for cell signaling in tumor cell proliferation, adhesion, and metastasis. The ubiquitous nature of uPAR in many aggressive cancer types makes uPAR an attractive target for immunotherapy. Here, we present a rapid and s...
Autores principales: | Lourenço, André Luiz, Chuo, Shih-Wei, Bohn, Markus F., Hann, Byron, Khan, Shireen, Yevalekar, Neha, Patel, Nitin, Yang, Teddy, Xu, Lina, Lv, Dandan, Drakas, Robert, Lively, Sarah, Craik, Charles S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988344/ https://www.ncbi.nlm.nih.gov/pubmed/36859773 http://dx.doi.org/10.1080/19420862.2023.2184197 |
Ejemplares similares
-
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
por: Harel, Efrat T., et al.
Publicado: (2019) -
Human antibody V(H) domains targeting uPAR as candidate therapeutics for cancers
por: Chu, Xiaojie, et al.
Publicado: (2023) -
Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging
por: Yang, Dongzhi, et al.
Publicado: (2016) -
Integrin is on uPAR to unleash cells
por: LeBrasseur, Nicole
Publicado: (2003) -
uPAR's signaling two step
por: Leslie, Mitch
Publicado: (2007)